Calyx (clinical research company)

CALYX

Company type	Private
Industry	Clinical research organizations Pharmaceutical
Founded	2021
Headquarters	Nottingham, United Kingdom[1]
Number of locations	12+ facilities in 10+ countries
Key people	CEO: David Herron
Services	Medical imaging, clinical trial management systems
Revenue	$82 million (2022)[2][3]
Number of employees	1000-2000[4]
Parent	CapVest Partners/GLO Healthcare
Website	calyx.ai

Calyx, formerly Parexel Informatics,[5] is a corporate spin-off from Parexel International.[2][6] Calyx is a British–American provider of biopharmaceutical services.[7] The company was formed in January 2021 following the strategic separation of the Parexel Informatics business from Parexel International, and provides medical imaging, e-clinical and regulatory services.[8][9]

References

1. https://www.calyx.ai/locations/
2. "Merck and Veeva Ink 10-Year Partnership Agreement". BioPharm International.
3. "Calyx Partnership with Top 5 CRO Extended through 2024". finance.yahoo.com.
4. "Company".
5. https://www.clinicalresearchnewsonline.com/news/2022/06/10/calyx-named-medical-imaging-provider-by-clinscience
6. "Calyx Spins Out of Parexel". Applied Clinical Trials Online.
7. "Announcing Calyx: Advancing Clinical Research Through Technology-Enabled Services".
8. "Announcing Calyx: Advancing Clinical Research Through Technology-Enabled Services". Retrieved 29 March 2023.
9. "Calyx rebrands as Perceptive. Introducing Perceptive: A New Name for the Global Leader in Discovery, eClinical, and Imaging Services and Solutions". Perceptive. 2024-12-16. Retrieved 2024-12-16.